<DOC>
	<DOCNO>NCT00669214</DOCNO>
	<brief_summary>This Phase IV randomize , double-blind , placebo-controlled study design evaluate safety efficacy subcutaneous efalizumab adult patient ( 18 year age old ) chronic moderate severe plaque psoriasis involvement scalp previous exposure efalizumab . The study consist screening period , double-blind treatment period , open-label treatment period , observation/follow-up period . The study enrol 100 patient . 11 patient excluded analysis data issue .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Efalizumab Adult Patients With Moderate Severe Plaque Psoriasis With Involvement Scalp</brief_title>
	<detailed_description>- Baselines Raptiva group placebo group Day 84 . The baseline Day 0 . - Baselines Raptiva group placebo group Day 168 different . The baseline Raptiva group Day 168 Day 0 , baseline Placebo group Day 168 Day 84</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Provide write informed consent Health Insurance Portability Accountability Act 1996 ( HIPAA ) document Be age 18 year old Have chronic ( 6 month great ) moderate severe plaque psoriasis involvement scalp Have whole body Physician 's Global Assessment ( PGA ) rating moderate ( 3 ) severe ( 4 ) psoriasis Have scalp surface area affect plaque psoriasis 30 % , assess use Psoriasis Scalp Severity Index ( PSSI ) Have least one three clinical sign involve scalp ( erythema , induration , desquamation ) rat least moderate ( 2 ) two rat least slight ( 1 ) use PSSI Be candidate systemic therapy opinion investigator Be naive efalizumab treatment For woman childbearing potential , must willing use method contraception acceptable investigator prevent pregnancy agree continue practice acceptable method contraception duration participation study 6 week last dose efalizumab Have previous exposure efalizumab history hypersensitivity component Are use exclude therapy Have history drug alcohol abuse past five year Have history past 5 year serious infection currently ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection Have history opportunistic infection ( e.g. , systemic fungal infection , parasite ) Are seropositive hepatitis B antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) Have history active tuberculosis currently undergo treatment tuberculosis , include latent tuberculosis isoniazid Have presence history malignancy within past 5 year , include lymphoproliferative disorder Are pregnant breastfeed Have diagnosis hepatic cirrhosis , regardless cause severity Have history last 5 year thrombocytopenia Have history last 5 year hemolytic anemia clinically significant anemia Have expose experimental and/or unapproved drug treatment within 30 day 5 halflives , whichever longer , screen visit Have vaccinate live virus live bacteria within 14 day first dose efalizumab Have medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug ( efalizumab placebo equivalent ) would significantly interfere patient 's ability comply provision protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Raptiva</keyword>
	<keyword>Moderate plaque psoriasis</keyword>
	<keyword>Severe plaque psoriasis</keyword>
	<keyword>Scalp</keyword>
</DOC>